AstraZeneca PLC
[WKN: 886455 | ISIN: GB0009895292]
Aktienkurse
125,525€ 0,82%
Echtzeit-Aktienkurs AstraZeneca PLC
Bid: Ask:
Reuters Kategorien
dpa-AFX Compact / dpa-AFX PRO Kategorien
Traderfox: dpa-AFX ProFeed Kategorien
dpa-AFX ProFeed Kategorien

1st Quarter Results

AstraZeneca 25 April 2024 Q1 2024 results Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery Revenue and…

ANGLE shares jump 30% on AstraZeneca tie-up

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) shares jumped 30% following the announcement of a strategic partnership with AstraZeneca PLC (LSE:AZN) that aims to advance...…

Result of AGM

11 April 2024 1730 BST Results of Annual General Meeting held on 11 April 2024 AstraZeneca PLC announced the results of the…

AstraZeneca increases 2024 dividend by 7%

11 April 2024  AstraZeneca increases 2024 dividend by 7% AstraZeneca announced today that the Board intends to increase the annualised dividend for…

BARCLAYS stuft ASTRAZENECA auf Overweight

LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Astrazeneca auf "Overweight" mit einem Kursziel von 12500…

Enhertu approved in US for HER2+ solid tumours

08 April 2024 Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours Based on…

Imfinzi improved OS & PFS in limited-stage SCLC

05 April 2024 Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase…

Total Voting Rights

2 April 2024 15:00 BST Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

FDA accepts Dato-DXd BLA for breast cancer

2 April 2024 Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast…

UBS stuft ASTRAZENECA auf Sell

ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 9900…